US 12,168,051 B2
Methods and compositions for stimulating immune response
Mahjoub Bihi, Mainz (DE); Ugur Sahin, Mainz (DE); Mustafa Diken, Mainz (DE); and Thorsten Klamp, Mainz (DE)
Assigned to BIONTECH SE, Mainz (DE); and TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz (DE)
Filed by BIONTECH SE, Mainz (DE); and TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT, Mainz (DE)
Filed on Sep. 12, 2022, as Appl. No. 17/931,215.
Application 17/931,215 is a continuation of application No. 16/496,858, granted, now 11,471,522, previously published as PCT/EP2018/057206, filed on Mar. 21, 2018.
Claims priority of application No. PCT/EP2017/057094 (WO), filed on Mar. 24, 2017.
Prior Publication US 2023/0074462 A1, Mar. 9, 2023
Int. Cl. A61K 48/00 (2006.01); A61K 39/145 (2006.01); C12N 15/11 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/145 (2013.01) [C12N 15/11 (2013.01); A61K 38/00 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01); C12N 2760/16134 (2013.01)] 24 Claims
OG exemplary drawing
 
1. An isolated RNA molecule comprising:
(i) the sequence of SEQ ID NO: 6 or a variant thereof, said variant having at least 90% sequence identity to SEQ ID NO: 6;
(ii) the sequence of SEQ ID NO: 7 or a variant thereof, said variant having at least 90% sequence identity to SEQ ID NO: 7;
(iii) the sequence of SEQ ID NO: 10 or a variant thereof, said variant having at least 90% sequence identity to SEQ ID NO: 10; or
(iv) the sequence of SEQ ID NO: 11 or a variant thereof, said variant having at least 90% sequence identity to SEQ ID NO: 11;
wherein the isolated RNA molecule comprises a modification which is not naturally present in the RNA.